MAGI2 antisense RNA 3 (MAGI2-AS3)

MAGI2 antisense RNA 3 (MAGI2-AS3) is a long non-coding RNA (lncRNA) transcribed from the 7q21.11 chromosomal locus and is involved in the post-transcriptional regulation of gene expression, primarily by functioning as a molecular sponge for multiple microRNAs[1][2][3][5]. This lncRNA is found in both the nucleus and cytoplasm, depending on the cell type[2]. MAGI2-AS3 is aberrantly expressed in various cancers, where it typically acts as a tumor suppressor, inhibiting cell proliferation, migration, invasion, and promoting apoptosis via interactions with cancer-associated microRNAs and regulation of downstream mRNAs[1][2][3][4][5]. Expression of MAGI2-AS3 is also linked to non-malignant conditions, including congenital diaphragmatic hernia, Alzheimer’s disease, and intervertebral disc degeneration[1]. Its expression can be epigenetically silenced by DNA methylation, which can be pharmacologically reversed[2]. Although MAGI2-AS3 itself is not a conventional therapeutic "target" like a receptor or enzyme, its role as a disease biomarker and regulator of cancer-related pathways makes it a focus of translational and biomarker research[1][2][3][4][5].

Other names

ENST00000414797MAGI2-AS3MAGI2 antisense RNA 3 (non-protein coding)lncRNA MAGI2-AS3

Not a direct drug target; however, inhibition or upregulation of MAGI2-AS3 affects cell phenotypes via post-transcriptional regulation of target mRNAs by sponging microRNAs[2][3][5]. Some targeted studies use gene knockdown or overexpression (e.g., by shRNA/siRNA or cDNA constructs) in cell culture and animal models[2][3][5].